Shengnuo Biotechnology (688117.SH): Plans to extend the "Formulation Industrialization Technology Renovation Project" of the fundraising project to June 2025.

On July 12th, Gelonhui reported that Santen Pharmaceutical (688117.SH) held the 21st meeting of the fourth board of directors and the 20th meeting of the fourth supervisory board on July 12, 2024 and approved the proposal on the delay of some raised investment projects. Considering the progress of the implementation of some raised investment projects (hereinafter referred to as "raised investment projects"), the company agreed to postpone the date when the raised investment project "formulation industrialization technology transformation project" reaches the planned usable status to June 2025.

Gelonghui FinanceJul 12 05:03 ET

Shengnuo Biotechnology (688117.SH): The application for the listing approval of Citric Acid Bivalirudin active pharmaceutical ingredient has been obtained.

On July 4th, Gelon Hui announced that its wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., recently received the "Approval Letter for Listing Application of Chemical Raw Materials for Citric Acid Bivalirudin Active Pharmaceutical Ingredient" issued by the National Medical Products Administration. Citric acid bivalirudin is used for perioperative antithrombotic therapy for PCI, can specifically bind to GP IIb/IIIa receptors, and inhibit platelet aggregation by blocking the combination of fibrinogen, von Willebrand factor and other adhesion ligands with GP IIb/IIIa. Citric acid bivalirudin not only

Gelonghui FinanceJul 4 05:25 ET

ChengDu ShengNuo Biotec Co.,Ltd.'s (SHSE:688117) Popularity With Investors Is Clear

When close to half the companies in China have price-to-earnings ratios (or "P/E's") below 29x, you may consider ChengDu ShengNuo Biotec Co.,Ltd. (SHSE:688117) as a stock to potentially avoid with its

Simply Wall StJun 20 18:34 ET

Shengnuo Biotech (688117.SH) plans to distribute 0.2 yuan per share in 2023, with ex-rights and ex-dividends on June 14th.

Shengnuo Biotech (688117.SH) announced that its 2023 annual equity distribution plan is to distribute to all shareholders...

Zhitong FinanceJun 6 05:37 ET

Shengnuo Biotech (688117.SH): The ban on 457.78,600 restricted shares was lifted on June 3

Gelonghui, May 24 | Shengnuo Biotech (688117.SH) announced that the total number of shares in circulation during the current stock listing was 457.78,600 shares. The current stock listing circulation date is June 3, 2024.

Gelonghui FinanceMay 24 05:40 ET

Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection

Chengdu Sirnao Biopharmaceutical, a unit of Chengdu Sheng Nuo Biotec (SHA:688117), received a drug registration certificate from China's National Medical Products Administration to produce its drug po

MT NewswiresMay 7 01:14 ET